AAL

Pharma Stock Soars to Record Highs After Epilepsy Treatment Results

The company reported positive data for its epilepsy treatment

Deputy Editor
Oct 4, 2021 at 1:32 PM
facebook X logo linkedin


Xenon Pharmaceuticals Inc (NASDAQ:XENE) stock is soaring today, up 90.8% to trade at $29.76 at last glance, after the company met its main goal in a phase 2 study of its epilepsy treatment XEN1101. Today's pop has XENE nabbing a fresh record high, as well as jumping over a slew of key moving averages and recent pressure at the $19 level. Year-over-year, the equity sports a 162.8% lead.
 
The options pits are bursting with activity. So far, 9,318 calls and 23,000 puts have crossed the tape, with volume pacing for the top percentile of its annual range, and already 10.9 times its usual daily average. The October 25 put is the most popular, followed by the 20 put in the same monthly series, with new positions being opened at both.
 
Plus, Jefferies raised its price target to $50 from $28, which is made more notable by the fact that analysts are already quite bullish on XENE. In fact, all six in coverage sport a "strong buy" rating on the stock, and the pre-adjustment 12-month consensus price target of $39.63 stands at a 33% premium to current levels. 

 

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.